Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1241-1260 of 1,738 trials

ADHD and Depression: Dexamfetamine Formulations Study

We are investigating the safety and effectiveness of two dexamfetamine sulfate formulations for adults with ADHD and moderate to severe depression. This study aims to see how these treatments compare to a placebo in improving symptoms and managing side effects.

Major DepressionAttention Deficit Hyperactivity Disorder (ADHD)3-6 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesPsychiatry

Chronic Myeloid Leukemia: Second Stop of TKI Treatment

We are studying whether patients with CML can maintain remission after stopping their medication for a second time. This trial aims to identify factors that may help in achieving better treatment outcomes.

Chronic Myeloid Leukemia>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Rett Syndrome: Testing Mirtazapine

We are studying whether Mirtazapine can improve social behavior, anxiety, and sleep quality in patients with Rett syndrome. This research may help us understand how to better manage symptoms of this condition.

Rett Syndrome6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyPsychiatry

Mucositis in Metastatic Renal Cell Carcinoma: Folic Acid Supplement Study

We are studying whether a folic acid supplement can help reduce mucositis in patients with metastatic renal cell carcinoma receiving targeted therapy. This trial will also assess the impact on quality of life and treatment side effects.

Metastatic Renal Cell Carcinoma≤3 monthsEfficacy phase (II)≤5 visitsStandard MedicinesInternal MedicineOncology

Heart Failure: Hyperpolarized MRI Study

We are investigating how the heart uses a substance called pyruvate in patients with heart failure. This study aims to see if a new imaging method can improve our understanding of heart metabolism.

Heart Failure>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Gestational Trophoblastic Neoplasias: Avelumab and Methotrexate Study

We are investigating a new treatment combining Avelumab and Methotrexate for individuals with low-risk gestational trophoblastic neoplasias. This study aims to see if this combination is a safe and effective first-line option.

Gestational Trophoblastic Tumor>2 yearsSafety phase (I)Efficacy phase (II)Gynecology and Obstetrics

Ovarian Cancer: Tinzaparin and Biomarkers

We are studying how tinzaparin affects cancer marker levels in patients with advanced ovarian cancer receiving chemotherapy. This trial also looks at the drug's safety and its impact on immune and blood factors.

Epithelial Ovarian Cancer6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Advanced Solid Tumors: ALE.P02 Treatment Study

We are investigating a new antibody-drug conjugate, ALE.P02, for adults with certain advanced solid tumors. The study aims to evaluate its safety and how well it may work against these tumors.

Advanced or Metastatic Squamous Solid Tumors1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboCost ReimbursementOncology

Aggressive Multiple Sclerosis: Stem Cell Transplant Study

We are investigating whether stem cell transplantation can prevent disease activity in people with aggressive multiple sclerosis. The study will also monitor safety and other health changes over time.

Relapsing-Remitting Multiple Sclerosis>2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyNeurology

Myocarditis: Anakinra Treatment Study

We are investigating whether adding Anakinra to standard treatments helps patients with virus-negative myocarditis. This study aims to evaluate its safety and effectiveness compared to usual care.

Virus-Negative Myocarditis6-12 monthsEfficacy phase (II)≤5 visitsStandard MedicinesCardiologyInternal Medicine

Kidney Transplant: Alkaline Phosphatase Treatment

We are studying whether alkaline phosphatase can help prevent kidney injury after transplantation in deceased donor recipients. This may reduce the need for dialysis and improve kidney function recovery.

End-Stage Kidney DiseaseEfficacy phase (II)Investigational MedicinesInternal MedicineNephrology

Artificial Cornea for Severe Corneal Ulcers

We are studying a new human-made cornea for patients with advanced corneal ulcers that don't improve with standard treatments. The trial aims to assess its safety and effectiveness in these challenging cases.

Corneal Ulcer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOphthalmology

Decompensated Cirrhosis: New Human Albumin Solution

We are studying a new human albumin solution to see if it is safer and more effective than the standard treatment for patients with decompensated cirrhosis. This research aims to improve clinical outcomes for those needing long-term albumin therapy.

Decompensated Cirrhosis1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHepatologyInternal Medicine

Atopic Dermatitis: RO7790121 Treatment Study

We are testing a new medication, RO7790121, for people with moderate to severe atopic dermatitis. The study aims to see if it can significantly improve skin symptoms compared to a placebo.

Atopic DermatitisEfficacy phase (II)≤5 visitsInvestigational MedicinesPartially RemoteAllergologyDermatology

Hematologic Malignancies: Gene-Modified T Cell Therapy

We are exploring a new treatment using modified T cells for patients with certain blood cancers who have received a transplant from specific donors. The study aims to see if this approach is safe and effective.

Hematological Malignancies with Specific HLA-DPB1 MarkersSafety phase (I)Efficacy phase (II)HematologyInfectious Diseases

Metastatic Urothelial Carcinoma: Livmoniplimab and Budigalimab Study

We are studying a new combination of livmoniplimab and budigalimab for adults with metastatic urothelial carcinoma who have not responded to prior treatments. The goal is to see if this combination improves survival compared to standard chemotherapy.

Urothelial CarcinomaMetastatic Urothelial CarcinomaEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Advanced Neuroendocrine Carcinomas: Enfortumab-Vedotin Study

We are studying a new treatment for patients with advanced Neuroendocrine Carcinomas who cannot use standard chemotherapy. The goal is to see if this treatment can help shrink tumors and improve survival.

Neuroendocrine Carcinoma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesEndocrinologyOncology

Osteogenesis Imperfecta: Losartan Therapy Study

We are investigating the right dose of losartan for older adolescents and adults with Osteogenesis Imperfecta. The study aims to see how it affects bone health and quality of life.

Brittle Bone Disease3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineOrthopedics and Traumatology

Diffuse Large B-Cell Lymphoma: Zilovertamab Vedotin with R-CHP

We are studying a new treatment combining zilovertamab vedotin with standard therapy for people with diffuse large B-cell lymphoma. The goal is to see if this combination works better than another treatment option.

Diffuse Large B-Cell Lymphoma>2 yearsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Head and Neck Cancer: INBRX-106 with Pembrolizumab

We are studying whether adding INBRX-106 to pembrolizumab helps patients with recurrent or metastatic head and neck cancer. This trial focuses on effectiveness, safety, and quality of life for those with high PD-L1 expression.

Head and Neck Squamous Cell CarcinomaEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementOncology